|
1.Date of the shareholders meeting resolution:2022/05/25
2.Name and title of the director with permission to engage in competitive
conduct:
Directors:Representative of CHINA CHEMICAL & PHARMACEUTICAL CO., LTD./
WANG HSIEH YI-CHEN
Directors:Representative of CHINA CHEMICAL & PHARMACEUTICAL CO., LTD./
WANG, HOU-KAI
Directors:Representative of WANG MING-NING MEMORIAL FOUNDATION./
HUANG ,JONG-SHINN
Directors:Representative of WANG MING-NING MEMORIAL FOUNDATION./
WANG, HOU -JIE
Independent Directors：WANG ,KUO-CHIANG
Independent Directors：CHANG ,CHIH-HSIEN
Independent Directors：KUAN ARTHUR
3.Items of competitive conduct in which the director is permitted to engage:
(1)Directors:Representative of CHINA CHEMICAL & PHARMACEUTICAL CO., LTD.
/WANG HSIEH YI-CHEN
A.Chairman of China Chemical & Pharmaceutical Co., Ltd. (Chunghwa
Chemical Synthesis & Biotech Co. Ltd. legal representative)
B.Chairman of Chunghwa Yuming Healthcare Co., Ltd. (China Chemical &
Pharmaceutical Co., Ltd. legal representative)
C.Chairman of Chunghwa Senior Care Co., Ltd. (China Chemical &
Pharmaceutical Co., Ltd. legal representative)
D.Chairman of Tairung Development Co., Ltd.
E.Chairman of HU-YU Co., Ltd.
F.Chairman of Majiade Enterprises Co., Ltd.
(2)Directors:Representative of CHINA CHEMICAL & PHARMACEUTICAL
CO., LTD./ WANG, HOU-KAI
Strategic Business Development Vice President, Chunghwa Yuming
Healthcare Co., Ltd.
(3)Directors:Representative of WANG MING-NING MEMORIAL FOUNDATION./
HUANG ,JONG-SHINN
A.President of Chunghwa Chemical Synthesis & Biotech Co., Ltd.
B.Chairman of PHARMAPORTS,LLC (Chunghwa Chemical Synthesis &
Biotech Co. Ltd. legal representative)
C.General director of Sino-Japan Chemical Co., Ltd. (China
Chemical & Pharmaceutical Co., Ltd. legal representative)
(4)Directors:Representative of WANG MING-NING MEMORIAL FOUNDATION./
WANG, HOU –JIE
A.Director and Vice President of Suzhou Chung-Hwa Chemical
Pharmaceutical Industrial Co., Ltd.
B.Director of China Chemical & Pharmaceutical Co., Ltd.
(Wang Ming-Ning Memorial Foundation legal representative)
C.Director of Tairung Development Co., Ltd.
(5)Independent Directors：WANG ,KUO-CHIANG
A.Davicom Semiconductor, Inc. managing director
B.Partner Tech Corp. independent director, remunerations
committee commissioner, audit committee commissioner.
C.Feedback Tech. Corp. independent director, remunerations
committees commissioner, audit committee commissioner,
merger special committee commissioner.
D.Independent Director, Convener of Compensation and Remuneration
Committee, and Convener of Audit Committee, Hill Source Holdings
Limited (KY Company)
E.Assistant Professor of National Yang Ming Chiao Tung University
(6)Independent Directors：CHANG ,CHIH-HSIEN
A.Vision Thinktank Co., Ltd. CEO
B.Special assistant to the hosting architect of Partners
Architects Planners
C.Head of Finance, JIA-TENG Construction Group
(7)Independent Directors：KUAN ARTHUR
A.Chairman and President (Acting), Allied Industrial Corp., Ltd.
B.Chief Executive Officer and Board Director, CG Oncology
(Eternal Facial Biotechnology Co., Ltd.)
C.Partner, Perseverance Capital Management
4.Period of permission to engage in the competitive conduct:
During the tenure of director post.
5.Circumstances of the resolution (please describe the results of voting in
accordance with Article 209 of the Company Act):
Approved by more than two-thirds of voting rights of attending
shareholders, who hold more than half of the total number of shares
issued.
6.If the permitted competitive conduct belongs to the operator of a mainland
China area enterprise, the name and title of the directors
(if it is not the operator of a Mainland-area enterprise, please enter
“N/A” below):
Directors:Representative of WANG MING-NING MEMORIAL FOUNDATION./
WANG, HOU –JIE
7.Company name of the mainland China area enterprise and the director's
position in the enterprise:
Director and Vice President of Suzhou Chung-Hwa Chemical Pharmaceutical
Industrial Co., Ltd.
8.Address of the mainland China area enterprise:
No. 66, Yongan Road, New District, Suzhou, Jiangsu
9.Operations of the mainland China area enterprise:
pharmaceutical products/ Production and sale of health care products
10.Impact on the company's finance and business:None
11.If the directors have invested in the mainland China area enterprise,
the monetary amount of the investment and their shareholding ratio:N/A
12.Any other matters that need to be specified:None
|
